Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2850-2860

  Wang, Hong ^a   Ru, Yuanbin ^a   Sanchez Carbayo, Marta ^d   Wang, Xuejiao ^e,f   Kieft, Jeffrey S ^b   Theodorescu, Dan ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Cellomics Technology LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLIN RB; CYCLINE; EUKARYOTIC INITIATION FACTOR 3B; INITIATION FACTOR; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL DISRUPTION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOCAL ADHESION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR GROWTH;

ACTINS; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-3; FEMALE; FOCAL ADHESIONS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; INTEGRIN ALPHA5; LUNG NEOPLASMS; MALE; MICE; NEOPLASMS; PHENOTYPE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 84878986697     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3084     Document Type: Article

References (50)

1. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
2. Pestova TV, Kolupaeva VG. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 2002;16:2906-22. (Pubitemid 35334739)
3. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136:731-45.
4. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010;115:2127-35.
5. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99. (Pubitemid 38638830)
6. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48. (Pubitemid 47494364)
7. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-4. (Pubitemid 351206735)
8. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010;16:4914-20.
9. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12:137-43.
10. Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res 2012;72:3480-91.
11. Dancik GM, Ru Y, Owens CR, Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res 2011;71:7398-409.
12. Hinnebusch AG. eIF3: a versatile scaffold for translation initiation complexes. Trends Biochem Sci 2006;31:553-62. (Pubitemid 44436942)
13. Dong Z, Zhang JT. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006;59:169-80. (Pubitemid 44294864)
14. Dong Z, Liu LH, Han B, Pincheira R, Zhang JT. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 2004;23:3790-801. (Pubitemid 38725692)
15. Mayeur GL, Hershey JW. Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e). FEBS Lett 2002;514:49-54. (Pubitemid 34251241)
16. Cappuzzo F, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, Drabkin H, et al. MYC and EIF3H coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol 2009;4:472-8.
17. Saramaki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 2001;159:2089-94. (Pubitemid 33104263)
18. Zhou M, Sandercock AM, Fraser CS, Ridlova G, Stephens E, Schenauer MR, et al. Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc Natl Acad Sci U S A 2008;105:18139-44.
19. Herrmannova A, Daujotyte D, Yang JC, Cuchalova L, Gorrec F, Wagner S, et al. Structural analysis of an eIF3 subcomplex reveals conserved interactions required for a stable and proper translation pre-initiation complex assembly. Nucleic Acids Res 2012;40:2294-311.
20. Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 2007;282:5790-800. (Pubitemid 47093731)
21. Lin L, Holbro T, Alonso G, Gerosa D, Burger MM. Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7. J Cell Biochem 2001;80:483-90. (Pubitemid 32127463)
22. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010;9:3.
23. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006;38:1386-96. (Pubitemid 44837560)
24. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
25. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011;121:132-47.
26. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004;64:7813-21. (Pubitemid 39446914)
27. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66:1917-22.
28. Oxford G, Owens CR, Titus BJ, Foreman TL, Herlevsen MC, Smith SC, et al. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res 2005;65:7111-20. (Pubitemid 41161240)
29. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000;27:252-63. (Pubitemid 30067454)
30. Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007;26:765-73. (Pubitemid 46204255)
31. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23. (Pubitemid 35364098)
32. Dransart E, Olofsson B, Cherfils J. RhoGDIs revisited: novel roles in Rho regulation. Traffic 2005;6:957-66. (Pubitemid 41472455)
33. Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. Eur J Cancer 2010;46:1252-9.
34. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol 2010;11:633-43.
35. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004;135:555-62. (Pubitemid 38586530)
36. Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010;70:1885-95.
37. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409-16. (Pubitemid 36527488)
38. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68. (Pubitemid 40064899)
39. Rothe M, Ko Y, Albers P, Wernert N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol 2000;157:1597-604.
40. Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011;71:3802-11.
41. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25:5220-7. (Pubitemid 44299080)
42. Jorgensen P, Tyers M. How cells coordinate growth and division. Curr Biol 2004;14:R1014-27. (Pubitemid 39623187)
43. Liang H, Ding X, Zhou C, Zhang Y, Xu M, Zhang C, et al. Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci 2012;33:1057-62.
44. Wang Z, Chen J, Sun J, Cui Z, Wu H. RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells. World J Surg Oncol 2012;10:119.
45. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-9. (Pubitemid 37505725)
46. Schwartz MA. Integrin signaling revisited. Trends Cell Biol 2001;11:466-70. (Pubitemid 33079137)
47. Morozevich G, Kozlova N, Cheglakov I, Ushakova N, Berman A. Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 2009;8:2219-25.
48. Mierke CT, Frey B, Fellner M, Herrmann M, Fabry B. Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 2011;124:369-83.
49. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-39. (Pubitemid 351521807)
50. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-13.